Infinity Pharmaceuticals Inc INFI:NASDAQ

Last Price$1.03Cboe Closing Price as of 4:00PM ET 8/10/22
Cboe Real-Time Quotes
Today's Change+0.29(39.19%)
Bid (Size)$0.92 (100)
Ask (Size)$1.08 (100)
Day Low / High$0.90 - 1.22
Volume3.2 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/10/2022


Infinity Pharmaceuticals Inc ( NASDAQ )

Price: $1.03
Change: +0.29 (39.19%)
Volume: 3.2 M
4:00PM ET 8/10/2022

Avalon Globocare Corp ( NASDAQ )

Price: $0.67
Change: 0.00 (0.00%)
Volume: 43.3 K
2:45PM ET 8/10/2022

Sellas Life Sciences Group Inc ( NASDAQ )

Price: $3.35
Change: +0.16 (4.85%)
Volume: 181.8 K
3:59PM ET 8/10/2022

9 Meters Biopharma Inc ( NASDAQ )

Price: $0.26
Change: +0.01 (5.24%)
Volume: 2.8 M
3:36PM ET 8/10/2022

Lumos Pharma Inc ( NASDAQ )

Price: $8.30
Change: +0.20 (2.47%)
Volume: 7.8 K
2:43PM ET 8/10/2022

Read more news Recent News

--B. Riley Lowers Infinity Pharmaceuticals' Price Target to $3 from $5 to Reflect Delay in Eganelisib's Development, Uncertainty on Timing of Partnership; Maintains Buy Rating
9:20AM ET 8/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (INFI) INFINITY PHARMACEUTICALS Reports Q2 Loss $-0.13
4:20PM ET 8/09/2022 MT Newswires


Infinity Pharmaceuticals Gets Nasdaq Warning for Lack of Compliance With Minimum Bid Price Rule
4:54PM ET 5/24/2022 MT Newswires

Infinity Pharmaceuticals (INFI) said Tuesday it received a letter from Nasdaq notifying it that for the last 30 business days the bid price of its shares...

Piper Sandler Adjusts Infinity Pharmaceuticals' Price Target to $3 from $4, Keeps Overweight Rating
11:13AM ET 5/23/2022 MT Newswires

Infinity Pharmaceuticals (INFI) has an average rating of buy and price targets ranging from $3 to $11, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionInfinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development segment. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA. View company web site for more details
Address1100 Massachusetts Avenue
Cambridge, Massachusetts 02138
Number of Employees25
Recent SEC Filing08/09/20228-K
Chairman & Chief Executive OfficerAdelene Q. Perkins
President & TreasurerLawrence E. Bloch
Vice President-FinanceMelissa Hackel
Chief Scientific OfficerStephane Peluso

Company Highlights

Price Open$0.88
Previous Close$0.74
52 Week Range$0.46 - 3.89
Market Capitalization$91.8 M
Shares Outstanding89.2 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.52
Beta vs. S&P 500N/A
Revenue$22.1 M
Net Profit Margin-2,254.97%
Return on Equity-175.11%

Analyst Ratings as of 07/14/2022

Consensus RecommendationConsensus Icon
Powered by Factset